David Kirn, Founder and CEO
Oct. 11 | 11:30am | UBC Ballroom
4D Molecular Therapeutics (4DMT) seeks to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution (TVE). TVE combines the power of directed evolution with over one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved AAV vectors are invented with the goals of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration; of transducing diseased cells in target tissues efficiently; of having reduced immunogenicity; and, where relevant, of having resistance to pre-existing antibodies.